In Silico Exploration of Novel Tubulin Inhibitors: A Combination of Docking and Molecular Dynamics Simulations, Pharmacophore Modeling, and Virtual Screening

Table 3

The pharmacokinetic properties prediction by SwissADME software.

Ligand	GI absorption			Cytochrome inhibitor			Bioavailability
		1	2	3	4	5
b	High	Yes	Yes	Yes	Yes	No	0.85
c	Low	Yes	Yes	No	Yes	Yes	0.55
9ІV-c	Low	NO	Yes	Yes	No	No	0.55

1: CYP1A2; 2: CYP2C19; 3: CYP2C9; 4: CYP2D6; 5: CYP3A4.